Voyager Therapeutics Inc
NASDAQ:VYGR

Watchlist Manager
Voyager Therapeutics Inc Logo
Voyager Therapeutics Inc
NASDAQ:VYGR
Watchlist
Price: 4.38 USD 0.46% Market Closed
Market Cap: 243.5m USD

Wall Street
Price Targets

VYGR Price Targets Summary
Voyager Therapeutics Inc

Wall Street analysts forecast VYGR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VYGR is 15.3 USD with a low forecast of 8.08 USD and a high forecast of 26.25 USD.

Lowest
Price Target
8.08 USD
84% Upside
Average
Price Target
15.3 USD
249% Upside
Highest
Price Target
26.25 USD
499% Upside
Voyager Therapeutics Inc Competitors:
Price Targets
688366
Shanghai Haohai Biological Technology Co Ltd
64% Upside
FDMT
4D Molecular Therapeutics Inc
208% Upside
REGN
Regeneron Pharmaceuticals Inc
8% Upside
URGN
Urogen Pharma Ltd
52% Upside
9926
Akeso Inc
49% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
27% Upside

Revenue
Forecast

Revenue Estimate
Voyager Therapeutics Inc

The compound annual growth rate of Voyager Therapeutics Inc's revenue for the next 4 years is -1%.

N/A
Past Growth
-1%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Voyager Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Voyager Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-45%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VYGR's stock price target?
Price Target
15.3 USD

According to Wall Street analysts, the average 1-year price target for VYGR is 15.3 USD with a low forecast of 8.08 USD and a high forecast of 26.25 USD.

What is Voyager Therapeutics Inc's Revenue forecast?
Projected CAGR
-1%

The compound annual growth rate of Voyager Therapeutics Inc's revenue for the next 4 years is -1%.

Back to Top